Welcome to our dedicated page for Aclarion SEC filings (Ticker: ACON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Aclarion, Inc. (NASDAQ: ACON), a healthcare technology company that uses Magnetic Resonance Spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms to support the diagnosis of chronic low back pain. Investors and analysts can review Aclarion’s official regulatory disclosures, including current reports, registration statements, and other filings submitted through the EDGAR system.
For ACON, SEC filings are a primary source of information on financing activities, capital structure, and strategic priorities. For example, a Form 8-K dated October 13, 2025 describes a Securities Purchase Agreement for a registered direct offering of common stock and pre-funded warrants, including expected gross proceeds, pricing terms, and intended use of proceeds. The filing also outlines the role of the placement agent and references the effective Form S-3 registration statement used for the offering.
Through this filings page, users can locate Aclarion’s periodic and transactional filings that detail how the company funds market development, clinical evidence generation, the CLARITY trial, product development and quality, and general corporate purposes. These documents help explain how Aclarion supports commercialization of its Nociscan SaaS platform and its broader strategy in the chronic low back pain market.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, financial implications, and risk factors in plain language. Real-time updates from EDGAR ensure that new 8-Ks, registration statements, and related documents appear promptly. Users can also review filings that relate to equity offerings and other capital markets activities, gaining a clearer view of Aclarion’s liquidity, financing approach, and commitments. This combination of raw filings and AI explanations allows readers to understand complex legal and financial disclosures without parsing every technical detail themselves.
Aclarion, Inc. reported that it has closed a previously disclosed registered direct offering of its common stock and pre-funded warrants. Under a Securities Purchase Agreement dated January 8, 2026, the company agreed to sell 200,000 shares of common stock at a price of $5.18 per share, or pre-funded warrants in lieu of shares, and pre-funded warrants to purchase up to 1,800,000 additional shares of common stock. The company stated in a January 13, 2026 press release that this offering closed on January 9, 2026.
Aclarion, Inc. entered into a Securities Purchase Agreement for a registered direct offering of 200,000 shares of common stock at $5.18 per share and pre-funded warrants to purchase up to 1,800,000 additional shares. The pre-funded warrants are immediately exercisable at an exercise price of $0.00001 per share and remain exercisable until fully exercised, subject to beneficial ownership caps of 4.99% or 9.99% unless adjusted with 61 days’ notice.
The company expects gross proceeds of about $10.36 million before fees and expenses and may receive nominal additional proceeds from any cash exercises of the pre-funded warrants. Aclarion plans to use net proceeds to fund market development and clinical evidence, The Clarity Trial, product development and quality, and general and administrative support and other general corporate purposes.
Aclarion, Inc. is conducting a primary offering of 200,000 shares of common stock and pre-funded warrants to purchase 1,800,000 shares, together with 1,800,000 shares issuable upon exercise of those pre-funded warrants. The securities are priced at $5.18 per share and $5.17999 per pre-funded warrant, for a total offering price of $10,359,982 and placement agent fees of $621,600, resulting in $9,738,382 in proceeds before expenses and estimated net proceeds of about $9.6 million.
The company plans to use the cash to fund market development and clinical evidence work, The Clarity Trial, product development and quality, and general and administrative support. Pre-funded warrants have a $0.00001 exercise price, do not expire, are subject to 4.99% (or, at the purchaser’s election, 9.99%) beneficial ownership limits, and will not be listed for trading. Common shares outstanding were 854,371 as of January 8, 2026 and are expected to be 2,854,371 assuming full cash exercise of the pre-funded warrants.
Aclarion, Inc. (ACON) reported Q3 2025 results. Revenue was $18,942, up modestly from $14,407 a year ago, with gross profit of $4,386 after a loss in the prior year period. Operating expenses rose to $1.84 million, leading to a net loss of $1.71 million versus $1.37 million a year earlier. For the first nine months, revenue reached $57,251 and net loss was $5.34 million.
The balance sheet strengthened following capital raises: cash and cash equivalents were $11.34 million versus $0.45 million at year‑end 2024, total assets were $13.20 million, liabilities were $0.70 million, and stockholders’ equity improved to $12.50 million. The company disclosed it raised an additional $2.5 million in October 2025 and believes its cash will fund operations through the first quarter of 2027. During 2025, Aclarion effected 1:335 and 1:27 reverse stock splits. Shares outstanding were 582,371 as of September 30, 2025; as context, 671,371 shares were outstanding as of November 10, 2025.
Aclarion, Inc. entered into a Securities Purchase Agreement for a registered direct offering, selling 64,000 shares of common stock at $8.36 per share and issuing pre-funded warrants to purchase up to 236,000 shares. The company expects approximately $2.5 million in gross proceeds, with closing anticipated on or about October 14, 2025, subject to customary conditions.
The pre-funded warrants are immediately exercisable at an exercise price of $0.00001 and include a beneficial ownership cap of 4.99% or 9.99%, adjustable with 61 days’ prior notice. Dawson James Securities is the exclusive placement agent and will receive a 7.0% cash fee on gross proceeds plus expense reimbursement. Aclarion plans to use net proceeds to fund market development and clinical evidence, The Clarity Trial, product development and quality, and general and administrative support, and other general corporate purposes.
Aclarion, Inc. launched a primary offering of 64,000 shares of common stock and pre-funded warrants for up to 236,000 shares under a Rule 424(b)(5) prospectus supplement. The shares are priced at $8.36 and the pre-funded warrants at $8.35999 each, with a nominal exercise price of $0.00001. The pre-funded warrants do not expire and are exercisable immediately, subject to a 4.99% (or, at the purchaser’s election, 9.99%) beneficial ownership cap.
Gross proceeds are $2,507,997.64. After a 7.0% placement fee payable to Dawson James Securities ($175,559.83), proceeds to the company before expenses are $2,332,437.81, with net proceeds estimated at approximately $2.2 million. The company plans to use the funds for market development and clinical evidence, The Clarity Trial, product development and quality, and general and administrative support.
Common stock trades on Nasdaq as ACON; the pre-funded warrants will not be listed. Shares outstanding were 582,371 as of June 30, 2025, and would be 882,371 assuming full cash exercise of the pre-funded warrants. Dawson James acted on a reasonable best efforts basis, with delivery expected on or about October 14, 2025.
FAQ
What is the current stock price of Aclarion (ACON)?
What is the market cap of Aclarion (ACON)?
